These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38644564)

  • 21. Relative Effectiveness of Influenza Vaccines Among the United States Elderly, 2018-2019.
    Izurieta HS; Chillarige Y; Kelman J; Wei Y; Lu Y; Xu W; Lu M; Pratt D; Wernecke M; MaCurdy T; Forshee R
    J Infect Dis; 2020 Jun; 222(2):278-287. PubMed ID: 32100009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.
    Patel SS; Bizjajeva S; Heijnen E; Oberye J
    Int J Infect Dis; 2019 Aug; 85S():S18-S25. PubMed ID: 31051279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.
    Song JY; Cheong HJ; Tsai TF; Chang HA; Choi MJ; Jeon JH; Kang SH; Jeong EJ; Noh JY; Kim WJ
    Vaccine; 2015 Aug; 33(36):4647-52. PubMed ID: 25980426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines in Adults During the 2019-2020 Influenza Season in the United States.
    Imran M; Ortiz JR; McLean HQ; Fisher L; O'Brien D; Bonafede M; Mansi JA; Boikos C
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac532. PubMed ID: 36320195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
    Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Pérez-Vilar S; Díez-Domingo J
    Vaccine; 2013 Aug; 31(37):3995-4002. PubMed ID: 23731629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic Assessment of High-Dose Versus Adjuvanted Influenza Vaccine: An Evaluation of Hospitalization Costs Based on a Cohort Study.
    van Aalst R; Gravenstein S; Mor V; Mahmud SM; Wilschut J; Postma M; Chit A
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
    Van Buynder PG; Konrad S; Van Buynder JL; Brodkin E; Krajden M; Ramler G; Bigham M
    Vaccine; 2013 Dec; 31(51):6122-8. PubMed ID: 23933368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.
    McElhaney JE; Beran J; Devaster JM; Esen M; Launay O; Leroux-Roels G; Ruiz-Palacios GM; van Essen GA; Caplanusi A; Claeys C; Durand C; Duval X; El Idrissi M; Falsey AR; Feldman G; Frey SE; Galtier F; Hwang SJ; Innis BL; Kovac M; Kremsner P; McNeil S; Nowakowski A; Richardus JH; Trofa A; Oostvogels L;
    Lancet Infect Dis; 2013 Jun; 13(6):485-96. PubMed ID: 23518156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
    Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis.
    Coleman BL; Sanderson R; Haag MDM; McGovern I
    Influenza Other Respir Viruses; 2021 Nov; 15(6):813-823. PubMed ID: 34081398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method.
    Young-Xu Y; Snider JT; van Aalst R; Mahmud SM; Thommes EW; Lee JKH; Greenberg DP; Chit A
    Vaccine; 2019 Mar; 37(11):1484-1490. PubMed ID: 30745146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B; Fierro C; Rosen J; Figueroa AL; Zhang B; Verhoeven C; Edelman J; Smolenov I
    Vaccine; 2020 Jan; 38(2):242-250. PubMed ID: 31635976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
    Cheong HJ; Song JY; Heo JY; Noh JY; Choi WS; Park DW; Wie SH; Kim WJ
    Clin Vaccine Immunol; 2011 Aug; 18(8):1358-64. PubMed ID: 21715575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study.
    Spadea A; Unim B; Colamesta V; Meneghini A; D'Amici AM; Giudiceandrea B; La Torre G
    Vaccine; 2014 Sep; 32(41):5290-4. PubMed ID: 25087677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019-2020 Influenza Season in the United States.
    Divino V; Ruthwik Anupindi V; DeKoven M; Mould-Quevedo J; Pelton SI; Postma MJ; Levin MJ
    Open Forum Infect Dis; 2022 Jan; 9(1):ofab604. PubMed ID: 35028334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvanted versus non-adjuvanted standard-dose influenza vaccines in preventing all-cause hospitalizations in the elderly: a cohort study with nested case-control analyses over 18 influenza seasons.
    Lapi F; Domnich A; Marconi E; Rossi A; Cricelli C
    Expert Rev Vaccines; 2022 Nov; 21(11):1647-1653. PubMed ID: 35984048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines Among Elderly Persons in the United States, 2017-2018.
    Izurieta HS; Chillarige Y; Kelman J; Wei Y; Lu Y; Xu W; Lu M; Pratt D; Chu S; Wernecke M; MaCurdy T; Forshee R
    J Infect Dis; 2019 Sep; 220(8):1255-1264. PubMed ID: 30561688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
    Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.